Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms

Lynne V. Abruzzo, Cecilia M. Rosales, L. Jeffrey Medeiros, Francisco Vega, Rajyalakshmi Luthra, John T. Manning, Michael J. Keating, Dan Jones

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

We describe five patients with treated low-grade B-cell neoplasms who subsequently developed Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorders (BLPDs). The low-grade B-cell neoplasms were B-cell chronic lymphocytic leukemia in four patients and splenic marginal zone lymphoma in one patient. All patients had received treatment with fludarabine for the low-grade B-cell neoplasm, and three had also received Campath-1H. The EBV-BLPDs arose 2-12 months after completion of fludarabine therapy and morphologically resembled the EBV-BLPDs that occur in the setting of iatrogenic immunodeficiency. Molecular genetic studies showed that these lesions were clonally distinct from the low-grade B-cell neoplasm in three of four cases assessed. Two patients did not receive therapy for the EBV-BLPD. The lesions regressed spontaneously in both patients but recurred in one. One patient underwent surgical excision and remains without evidence of the EBV-BLPD. One patient received aggressive multiagent chemotherapy with a complete response initially, but the EBV-BLPD recurred after 12 months. One patient received antiviral therapy and responded completely but died 2 months later of an opportunistic infection. We conclude that patients with low-grade B-cell neoplasms treated with fludarabine, possibly in combination with other immune suppressive agents, may subsequently develop EBV-BLPDs that morphologically resemble other iatrogenic immunodeficiency-associated BLPDs. Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy.

Original languageEnglish
Pages (from-to)630-636
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume26
Issue number5
DOIs
StatePublished - May 6 2002
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Human Herpesvirus 4
B-Lymphocytes
Neoplasms
fludarabine
Therapeutics
Opportunistic Infections
B-Cell Chronic Lymphocytic Leukemia
Antiviral Agents
Molecular Biology
Lymphoma

Keywords

  • Barr virus
  • Epstein
  • Fludarabine
  • Immunosuppression
  • Lymphoma
  • Lymphoproliferative disorder

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. / Abruzzo, Lynne V.; Rosales, Cecilia M.; Medeiros, L. Jeffrey; Vega, Francisco; Luthra, Rajyalakshmi; Manning, John T.; Keating, Michael J.; Jones, Dan.

In: American Journal of Surgical Pathology, Vol. 26, No. 5, 06.05.2002, p. 630-636.

Research output: Contribution to journalArticle

Abruzzo, Lynne V. ; Rosales, Cecilia M. ; Medeiros, L. Jeffrey ; Vega, Francisco ; Luthra, Rajyalakshmi ; Manning, John T. ; Keating, Michael J. ; Jones, Dan. / Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. In: American Journal of Surgical Pathology. 2002 ; Vol. 26, No. 5. pp. 630-636.
@article{3cc7cbf343af4a3e9a62855bc109c57c,
title = "Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms",
abstract = "We describe five patients with treated low-grade B-cell neoplasms who subsequently developed Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorders (BLPDs). The low-grade B-cell neoplasms were B-cell chronic lymphocytic leukemia in four patients and splenic marginal zone lymphoma in one patient. All patients had received treatment with fludarabine for the low-grade B-cell neoplasm, and three had also received Campath-1H. The EBV-BLPDs arose 2-12 months after completion of fludarabine therapy and morphologically resembled the EBV-BLPDs that occur in the setting of iatrogenic immunodeficiency. Molecular genetic studies showed that these lesions were clonally distinct from the low-grade B-cell neoplasm in three of four cases assessed. Two patients did not receive therapy for the EBV-BLPD. The lesions regressed spontaneously in both patients but recurred in one. One patient underwent surgical excision and remains without evidence of the EBV-BLPD. One patient received aggressive multiagent chemotherapy with a complete response initially, but the EBV-BLPD recurred after 12 months. One patient received antiviral therapy and responded completely but died 2 months later of an opportunistic infection. We conclude that patients with low-grade B-cell neoplasms treated with fludarabine, possibly in combination with other immune suppressive agents, may subsequently develop EBV-BLPDs that morphologically resemble other iatrogenic immunodeficiency-associated BLPDs. Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy.",
keywords = "Barr virus, Epstein, Fludarabine, Immunosuppression, Lymphoma, Lymphoproliferative disorder",
author = "Abruzzo, {Lynne V.} and Rosales, {Cecilia M.} and Medeiros, {L. Jeffrey} and Francisco Vega and Rajyalakshmi Luthra and Manning, {John T.} and Keating, {Michael J.} and Dan Jones",
year = "2002",
month = "5",
day = "6",
doi = "10.1097/00000478-200205000-00009",
language = "English",
volume = "26",
pages = "630--636",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms

AU - Abruzzo, Lynne V.

AU - Rosales, Cecilia M.

AU - Medeiros, L. Jeffrey

AU - Vega, Francisco

AU - Luthra, Rajyalakshmi

AU - Manning, John T.

AU - Keating, Michael J.

AU - Jones, Dan

PY - 2002/5/6

Y1 - 2002/5/6

N2 - We describe five patients with treated low-grade B-cell neoplasms who subsequently developed Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorders (BLPDs). The low-grade B-cell neoplasms were B-cell chronic lymphocytic leukemia in four patients and splenic marginal zone lymphoma in one patient. All patients had received treatment with fludarabine for the low-grade B-cell neoplasm, and three had also received Campath-1H. The EBV-BLPDs arose 2-12 months after completion of fludarabine therapy and morphologically resembled the EBV-BLPDs that occur in the setting of iatrogenic immunodeficiency. Molecular genetic studies showed that these lesions were clonally distinct from the low-grade B-cell neoplasm in three of four cases assessed. Two patients did not receive therapy for the EBV-BLPD. The lesions regressed spontaneously in both patients but recurred in one. One patient underwent surgical excision and remains without evidence of the EBV-BLPD. One patient received aggressive multiagent chemotherapy with a complete response initially, but the EBV-BLPD recurred after 12 months. One patient received antiviral therapy and responded completely but died 2 months later of an opportunistic infection. We conclude that patients with low-grade B-cell neoplasms treated with fludarabine, possibly in combination with other immune suppressive agents, may subsequently develop EBV-BLPDs that morphologically resemble other iatrogenic immunodeficiency-associated BLPDs. Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy.

AB - We describe five patients with treated low-grade B-cell neoplasms who subsequently developed Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorders (BLPDs). The low-grade B-cell neoplasms were B-cell chronic lymphocytic leukemia in four patients and splenic marginal zone lymphoma in one patient. All patients had received treatment with fludarabine for the low-grade B-cell neoplasm, and three had also received Campath-1H. The EBV-BLPDs arose 2-12 months after completion of fludarabine therapy and morphologically resembled the EBV-BLPDs that occur in the setting of iatrogenic immunodeficiency. Molecular genetic studies showed that these lesions were clonally distinct from the low-grade B-cell neoplasm in three of four cases assessed. Two patients did not receive therapy for the EBV-BLPD. The lesions regressed spontaneously in both patients but recurred in one. One patient underwent surgical excision and remains without evidence of the EBV-BLPD. One patient received aggressive multiagent chemotherapy with a complete response initially, but the EBV-BLPD recurred after 12 months. One patient received antiviral therapy and responded completely but died 2 months later of an opportunistic infection. We conclude that patients with low-grade B-cell neoplasms treated with fludarabine, possibly in combination with other immune suppressive agents, may subsequently develop EBV-BLPDs that morphologically resemble other iatrogenic immunodeficiency-associated BLPDs. Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy.

KW - Barr virus

KW - Epstein

KW - Fludarabine

KW - Immunosuppression

KW - Lymphoma

KW - Lymphoproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=0036227625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036227625&partnerID=8YFLogxK

U2 - 10.1097/00000478-200205000-00009

DO - 10.1097/00000478-200205000-00009

M3 - Article

C2 - 11979093

AN - SCOPUS:0036227625

VL - 26

SP - 630

EP - 636

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -